Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Imbruvica (ibrutinib) - Important Safety Information from Janssen-Cilag Limited as approved by the HPRA
Notice type:
3rd Party Publications
Date:
18/07/2017
Problem Or Issue:
Important Safety Information communication from Janssen-Cilag Limited on risk of hepatitis B reactivation: Hepatitis B virus status to be established before initiating treatment with Imbruvica (ibrutinib).
Important Safety Information - Imbruvica (ibrutinib)
« Back
Date Printed: 25/04/2024